Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bumetanide in Children and Adolescents with ASD
NCT03715166Phase 3Terminated
- Sponsor
- Servier
- Start
- Sep 2018
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 3 trial of bumetanide in Autism Spectrum Disorder (ASD), sponsored by Servier. Started Sep 2018; status: terminated.
02
Drugs
bumetanide
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT03715166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03715166.